Download PDF
Dtsch Med Wochenschr 2014; 139(40): 1999-2002
DOI: 10.1055/s-0034-1387287
Infektiologie | Commentary
Infektiologie, Hämatologie, Onkologie, Rheumatologie
© Georg Thieme Verlag KG Stuttgart · New York

Infektionsprophylaxe bei Immunsuppression

Prevention of infections in immune deficiency
B. Lange
1   IFB-Zentrum für Chronische Immundefizienz (CCI)
2   Abteilung Infektiologie, Universitätsklinikum Freiburg
,
S. Neumann
3   Interdisziplinäres ambulantes Onkologiezentrum, Wolfsburg
,
H. H. Hirsch
4   Klinik für Infektiologie und Spitalhygiene, Universitätsspital Basel
5   Departement Biomedizin (Haus Petersplatz), Universität Basel
,
W. V. Kern
2   Abteilung Infektiologie, Universitätsklinikum Freiburg
› Author Affiliations
Further Information

Publication History

Publication Date:
25 September 2014 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

Neutropenie - Immundefizienz - Antibiotikatherapie

Keywords

neutropenia - immune deficiency - antibiotics
 

  • Literatur

  • 1 Adamu B, Abdu A, Abba AA et al. Antibiotic prophylaxis for preventing post solid organ transplant tuberculosis. . Cochrane Database Syst Rev 2014; 3 CD008597
    PubMedGoogle Scholar
  • 2 Boršo D, Löbermann M, Fritzsche C et al. Impfen bei Immundefekten oder medikamentöser Immunsuppression. Dtsch Med Wochenschr 2013; 138: 145-150
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Bumbacea D, Arend SM, Eyuboglu F et al. The risk of tuberculosis in transplant candidates and recipients: a TBNET consensus statement. Europ Resp J 2012; 40: 990-1013
    PubMedGoogle Scholar
  • 4 Cantini F, Niccoli L, Goletti D. Tuberculosis risk in patients treated with non-anti-tumor necrosis factor-α (TNF-α) targeted biologics and recently licensed TNF-α inhibitors: data from clinical trials and national registries. J Rheumatol Suppl 2014; 91: 56-64
    CrossrefPubMedGoogle Scholar
  • 5 Chee CB, Sester M, Zhang W et al. Diagnosis and treatment of latent infection with Mycobacterium tuberculosis. Respirology 2013; 18: 205-216
    CrossrefPubMedGoogle Scholar
  • 6 Chemaly RF, Ullmann AJ, Stoelben S et al. Letermovir for cytomegalovirus prophylaxis in hematopoietic-cell transplantation. New Engl J Med 2014; 370: 1781-1789
    CrossrefPubMedGoogle Scholar
  • 7 Chong Y, Shimoda S, Yakushiji H et al. Clinical impact of fluoroquinolone-resistant Escherichia coli in the fecal flora of hematological patients with neutropenia and levofloxacin prophylaxis. PLoS One 2014; 9: e85210
    CrossrefPubMedGoogle Scholar
  • 8 Esfeh JM, Hanouneh IA, Koval CE et al. Impact of pretransplant rifaximin therapy on early post-liver transplant infections. Liver Transpl 2014; 20: 544-551
    CrossrefPubMedGoogle Scholar
  • 9 Gafter-Gvili A, Fraser A, Paul M et al. Antibiotic prophylaxis for bacterial infections in afebrile neutropenic patients following chemotherapy. Cochrane Database Syst Rev 2012; 3 CD004386
    PubMedGoogle Scholar
  • 10 Hasse B, Walker AS, Fehr J et al. Co-trimoxazole prophylaxis is associated with reduced risk of incident tuberculosis in participants in the Swiss HIV Cohort Study. Antimicrob Agents Chemother 2014; 58: 2363-2368
    CrossrefPubMedGoogle Scholar
  • 11 Horwedel TA, Bowman LJ, Saab G et al. Benefits of sulfamethoxazole-trimethoprim prophylaxis on rates of sepsis after kidney transplant. Transpl Infect Dis 2014; 16: 261-269
    CrossrefPubMedGoogle Scholar
  • 12 Huang YH, Hsiao LT, Hong YC et al. Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 2013; 31: 2765-2772
    CrossrefPubMedGoogle Scholar
  • 13 Katchman E, Marquez M, Bazerbachi F et al. A comparative study of the use of selective digestive decontamination prophylaxis in living-donor liver transplant recipients. Transpl Infect Dis 2014; 16: 539-547
    CrossrefPubMedGoogle Scholar
  • 14 König C, Kleber M, Reinhardt H et al. Incidence, risk factors, and implemented prophylaxis of varicella zoster virus infection, including complicated varicella zoster virus and herpes simplex virus infections, in lenalidomide-treated multiple myeloma patients. Ann Hematol 2014; 93: 479-484
    CrossrefPubMedGoogle Scholar
  • 15 Lübbert C, Faucheux S, Becker-Rux D et al. Rapid emergence of secondary resistance to gentamicin and colistin following selective digestive decontamination in patients with KPC-2-producing Klebsiella pneumoniae. Int J Antimicrob Agents 2013; 42: 565-570
    CrossrefPubMedGoogle Scholar
  • 16 Manuel O, Kralidis G, Mueller NJ et al. Impact of antiviral preventive strategies on the incidence and outcomes of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2013; 13: 2402-2410
    CrossrefPubMedGoogle Scholar
  • 17 McLaughlin JM, Equils O, Somerville KT et al. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients. Transpl Infect Dis 2013; 15: 329-343
    CrossrefPubMedGoogle Scholar
  • 18 Meije Y, Fortún J, Len Ó et al. Prevention strategies for cytomegalovirus disease and long-term outcomes in the high-risk transplant patient (D+/R-): experience from the RESITRA-REIPI cohort. Transpl Infect Dis 2014; 16: 387-396
    CrossrefPubMedGoogle Scholar
  • 19 Mitsides N, Greenan K, Green D et al. Complications and outcomes of trimethoprim-sulphamethoxazole as chemoprophylaxis for pneumocystis pneumonia in renal transplant recipients. Nephrology 2014; 19: 157-163
    CrossrefPubMedGoogle Scholar
  • 20 Neofytos D, Treadway S, Ostrander D et al. Epidemiology, outcomes, and mortality predictors of invasive mold infections among transplant recipients: a 10-year, single-center experience. Transpl Infect Dis 2013; 15: 233-242
    CrossrefPubMedGoogle Scholar
  • 21 Neumann S, Krause SW, Maschmeyer G et al. Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors. Ann Hematol 2013; 92: 433-442
    CrossrefPubMedGoogle Scholar
  • 22 Owers DS, Webster AC, Strippoli GF et al. Pre-emptive treatment for cytomegalovirus viraemia to prevent cytomegalovirus disease in solid organ transplant recipients. . Cochrane Database Syst Rev 2013; 2 CD005133
    PubMedGoogle Scholar
  • 23 Pyle RC, Butterfield JH, Volcheck GW et al. Successful outpatient graded administration of trimethoprim-sulfamethoxazole in patients without HIV and with a history of sulfonamide adverse drug reaction. J Allergy Clin Immunol Pract 0201; 2 (01) 52-58
    PubMedGoogle Scholar
  • 24 Roman A, Manito N, Campistol JM et al. The impact of the prevention strategies on the indirect effects of CMV infection in solid organ transplant recipients. Transplant Rev (Orlando) 2014; 28 (02) 84-91
    CrossrefPubMedGoogle Scholar
  • 25 Schaenman JM. Is universal antifungal prophylaxis mandatory in lung transplant patients?. Curr Opin Infect Dis 2013; 26: 317-325
    CrossrefPubMedGoogle Scholar
  • 26 Seetharam A, Perrillo R, Gish R. Immunosuppression in patients with chronic hepatitis B. Curr Hepatol Rep 2014; 13: 235-244
    PubMedGoogle Scholar
  • 27 Souto A, Maneiro JR, Salgado E et al. Risk of tuberculosis in patients with chronic immune-mediated inflammatory diseases treated with biologics and tofacitinib: a systematic review and meta-analysis of randomized controlled trials and long-term extension studies. Rheumatology (Oxford) 2014; 53: 1872-1885
    CrossrefPubMedGoogle Scholar
  • 28 Tacke D, Buchheidt D, Karthaus M et al. Primary prophylaxis of invasive fungal infections in patients with haematologic malignancies. 2014 update of the recommendations of the Infectious Diseases Working Party of the German Society for Haematology and Oncology. Ann Hematol 2014; 93 (09) 1449-1456
    CrossrefPubMedGoogle Scholar
  • 29 Verlinden A, Jansens H, Goossens H et al. Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. Eur J Haematol 2014; 93: 302-308
    CrossrefPubMedGoogle Scholar
  • 30 Wald A, Corey L, Timmler B et al. Helicase-primase inhibitor pritelivir for HSV-2 infection. New Engl J Med 2014; 370: 201-210
    CrossrefPubMedGoogle Scholar